WATCH LIVE
timothy sykes logo
MRNA Stock Surges As Flu Win And CAR-T Hype Ignite Rally Thumbnail
G Google News

MRNA Stock Surges As Flu Win And CAR-T Hype Ignite Rally

TIM SYKES•UPDATED JUL. 2, 2026, 11:34 AM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Moderna Inc. stocks have been trading up by 7.13 percent after strong mRNA pipeline progress fueled renewed investor optimism.

Key Takeaways For MRNA Traders

  • Unanimous FDA advisory backing for Moderna’s mRNA-1010/mFLUSIVA flu shot strongly supports its Biologics License Application ahead of the 2026/08/05 PDUFA decision.
  • FDA advisers endorsed full approval for adults 50–64 and accelerated approval for 65+, sparking about a 4% intraday pop in MRNA.
  • Science Day showed Moderna’s mRNA machine expanding into oncology and autoimmune disease, including T-cell engagers and an in vivo CAR-T program.
  • Piper Sandler boosted its MRNA price target from $69 to $77 with an Overweight call as the stock ripped through the mid-$60s.
  • Recent MRNA sessions saw 12%–14% jumps as traders chased momentum around the mRNA-6007 in vivo CAR-T story and a broadening pipeline.

Candlestick Chart

Live Update At 11:32:26 EDT: On Thursday, July 02, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 7.13%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MRNA has flipped from sleepy to fast-moving. On the daily chart, Moderna ran from a low near $45.99 on 2026/06/10 to $77.93 by 2026/07/02. That’s roughly a 70% swing in just a few weeks. For momentum traders, that kind of trend plus expanding ranges is exactly what you look for.

Intraday, the 5‑minute tape shows MRNA gapping from the low $70s to the mid‑$70s at the open, then spiking to $81.40 before settling just under $78. Dip buyers stepped in multiple times around $76–$77, suggesting aggressive support on pullbacks.

Fundamentally, Moderna is still in “build mode.” Quarterly revenue sits around $389M, with trailing revenue near $1.94B, but the company posted a net loss of about $1.34B in the latest quarter and an EBITDA loss of roughly $1.28B. Profit margins are deeply negative and free cash flow was about -$692M.

More Breaking News

The balance sheet, however, gives MRNA room to swing. Cash and short-term investments total about $5.21B, current ratio is 2.4, and long-term debt is a manageable $1.25B. For traders, that means dilution and burn are real, but a cash crunch is not the near-term story. The story is whether the pipeline can justify this fresh run.

Why Traders Are Watching MRNA Momentum

The real spark for MRNA wasn’t just a chart breakout. It was a regulatory and pipeline one‑two punch.

First, the FDA’s advisory committee (VRBPAC) voted 9‑0 that Moderna’s mRNA‑1010 / mFLUSIVA seasonal flu vaccine has a favorable benefit‑risk profile in adults 50–64 and 65+. FDA advisers backed full approval for the 50–64 group and accelerated approval for 65+. For a company trying to move beyond COVID, that’s a big deal. It de‑risks Moderna’s first major non‑COVID vaccine and sets up a clear shot at commercialization once the 2026/08/05 PDUFA date rolls around.

Traders saw that and reacted fast. One headline pegs MRNA up about 4% intraday on the flu news alone. Another notes a broader advisory recommendation for adults 50+, signaling the market that diversification beyond COVID is no longer theory — it’s lining up for reality.

Then Moderna staged its Science Day. Management laid out T‑cell engager data in multiple myeloma (mRNA‑2808), a follow‑on ovarian cancer program (mRNA‑2151), and plans to start clinical development of in vivo CAR‑T candidate mRNA‑6007 in 2027. That last piece — mRNA‑6007 — triggered nearly a 12% jump in MRNA as traders piled into the high‑risk, high‑reward oncology angle.

On top of that, MRNA now highlights four approved products, a growing infectious disease franchise, and a data/AI‑driven R&D engine. Piper Sandler responded by lifting its price target from $69 to $77, reiterating Overweight, while shares ripped through the $60s and into the $70s. At the same time, Jefferies kept a Hold with a $45 target and flagged that meaningful flu revenue may not show until around 2027. That split keeps MRNA a battleground name — perfect for active trading.

Conclusion

MRNA is shifting from a “COVID one‑hit wonder” narrative toward a multi‑pillar mRNA story. The unanimous FDA advisory votes around mRNA‑1010 / mFLUSIVA tell traders this flu launch is now more a question of timing and execution than basic scientific risk. If Moderna converts that into a durable flu franchise, it adds a new revenue column that helps offset shrinking pandemic-era sales.

The Science Day playbook matters just as much. By spotlighting oncology assets like mRNA‑2808, mRNA‑2151, and especially in vivo CAR‑T candidate mRNA‑6007, Moderna signaled that it wants to be a long‑term platform, not just a vaccine shop. The market’s 12%–14% pops in MRNA after these updates show traders are willing to pay for that optionality — at least in the short term.

Still, the financials remind everyone this is not a steady cash cow. MRNA is burning cash, margins are negative, and much of the value is tied to 2027+ execution. The Street is split: Piper Sandler’s $77 target and Overweight stand against a broader Hold consensus and lower average target.

For active traders, that tension is opportunity. Strong catalysts, clean technicals, and divided opinions can fuel big swings both ways. As Tim Sykes likes to say, “Volatility is your friend if you respect it — and your worst enemy if you don’t.” As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” Those trading rules are especially relevant in a name like MRNA that can move sharply on headlines. MRNA now sits firmly in that high‑volatility, catalyst‑rich zone, making it a name to study closely, manage risk tightly, and trade with a clear plan — strictly for educational and research purposes, not as trading advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”